Receipts at the Pharmacy Counter

The money, at a glance

independent expenditure supporting independent expenditure opposing backer or affiliation (no amount, no control)thicker line = more money

The diagram is a summary. Every relationship it draws is listed below with its type, direction, exact amount, geography, how the amount was verified, and its receipts.

Every relationship, in full

Verified against FEC filings: $0.00 across 0 flows, summed from itemized records
Reported, not independently verified: ~$4.5M across 6 flows. Deliberately not added to the figure above: an estimate plus an exact filing total is neither.

Money relationships in Receipts at the Pharmacy Counter. An independent expenditure supporting a candidate is not money that candidate received.
From → to	Relationship	Direction	Amount	How it was established	Geography	Receipts
Center Forward to Sen. Kyrsten Sinema (D-AZ)	spent supportingIndependent expenditure advocating for this candidate. The candidate did not receive or control this money.	supports	~$1.2MUSD, rounded	ReportedPublished by a news or research organization; not checked against primary filings here.	Arizona	Source
Pharmaceutical Research and Manufacturers of America (PhRMA) to Sen. Kyrsten Sinema (D-AZ)	contributed toMoney received by the recipient.	supports	~$466,000 (industry aggregate: many pharma PACs and individuals, not one committee)USD, rounded	ReportedPublished by a news or research organization; not checked against primary filings here.	Arizona	Source
Pharmaceutical Research and Manufacturers of America (PhRMA) to Rep. Scott Peters (D-CA-52)	contributed toMoney received by the recipient.	supports	$63,900 (industry aggregate: many pharma PACs and individuals, not one committee)USD, rounded	ReportedPublished by a news or research organization; not checked against primary filings here.	California	Source
Pharmaceutical Research and Manufacturers of America (PhRMA) to Rep. Kurt Schrader (D-OR-5)	contributed toMoney received by the recipient.	supports	$614,830 (career industry aggregate, not one committee)USD, rounded	ReportedPublished by a news or research organization; not checked against primary filings here.	Oregon	Source
Center Forward to Rep. Kurt Schrader (D-OR-5)	spent supportingIndependent expenditure advocating for this candidate. The candidate did not receive or control this money.	supports	$1.0MUSD, rounded	ReportedPublished by a news or research organization; not checked against primary filings here.	Oregon	Source
Pharmaceutical Research and Manufacturers of America (PhRMA) to Sen. Robert Menendez (D-NJ)	contributed toMoney received by the recipient.	supports	~$1.1M (career industry aggregate, not one committee)USD, rounded	ReportedPublished by a news or research organization; not checked against primary filings here.	New Jersey	Source

Backers and affiliations (11) — association only, no amount and no control asserted

Pfizer is associated with Pharmaceutical Research and Manufacturers of America (PhRMA)Backer or affiliation only. Not ownership, not control, not coordination.
Eli Lilly is associated with Pharmaceutical Research and Manufacturers of America (PhRMA)Backer or affiliation only. Not ownership, not control, not coordination.
Merck is associated with Pharmaceutical Research and Manufacturers of America (PhRMA)Backer or affiliation only. Not ownership, not control, not coordination.
AbbVie is associated with Pharmaceutical Research and Manufacturers of America (PhRMA)Backer or affiliation only. Not ownership, not control, not coordination.
Bristol-Myers Squibb is associated with Pharmaceutical Research and Manufacturers of America (PhRMA)Backer or affiliation only. Not ownership, not control, not coordination.
Johnson & Johnson is associated with Pharmaceutical Research and Manufacturers of America (PhRMA)Backer or affiliation only. Not ownership, not control, not coordination.
Amgen is associated with Pharmaceutical Research and Manufacturers of America (PhRMA)Backer or affiliation only. Not ownership, not control, not coordination.
Novo Nordisk is associated with Pharmaceutical Research and Manufacturers of America (PhRMA)Backer or affiliation only. Not ownership, not control, not coordination.
PhRMA ($4.5M donated 2016–2019, >25% of revenue) is associated with Center ForwardBacker or affiliation only. Not ownership, not control, not coordination.
undisclosed corporate donors is associated with Center ForwardBacker or affiliation only. Not ownership, not control, not coordination.
Pfizer Inc. is associated with Pfizer Inc. PACBacker or affiliation only. Not ownership, not control, not coordination.

Funder → recipient → message

No message on this page has a receipt tying a specific funder to a specific recipient, so no chain is drawn. A general note about a funder's ad strategy is not evidence that any individual politician authored, received, or was the subject of that message.

The 2022 Inflation Reduction Act gave Medicare the power to negotiate drug prices for the first time in two decades, but only after the pharmaceutical industry spent a record $380 million lobbying Congress and deployed surgical PAC contributions and dark-money advertising to blunt the legislation. The version that passed was dramatically narrower than Democrats' original proposal: capped at 20 drugs by 2029 and limited to older drugs past patent exclusivity, rather than the 250 drugs initially targeted. The key moderate Democrats who shaped those limits were Kyrsten Sinema (AZ), Scott Peters (CA), Kurt Schrader (OR), and Robert Menendez (NJ). They collected hundreds of thousands from pharma PACs and benefited from millions in industry-backed dark-money ads.

The pattern is documented with receipts: Peters collected $63,900 from pharma in the first half of 2021 (his single largest industry donor), including $19,600 from pharma executives and lobbyists within two days of signing a letter opposing Speaker Pelosi's negotiation bill. Sinema blocked the broader plan while a PhRMA-bankrolled front group spent $1.2M on ads supporting her. Schrader voted against negotiation in committee, lost his 2022 primary despite $1M in pharma-backed outside spending, and within a year joined a D.C. lobby firm representing Pfizer, Merck, and Eli Lilly, the same companies that funded his campaigns.

The funders

Pharmaceutical Research and Manufacturers of America (PhRMA)

Pro-pharma

Coalition / trade association · Pharma industry · FEC C00021972

Identity verified. Committee totals for C00021972 were retrieved from FEC on 2026-09-13. These are the PAC's finances, not PhRMA's overall revenue or its members' spending.

Ten years of this committee's reported finances

Backers and affiliations (association only)

• Pfizer
• Eli Lilly
• Merck
• AbbVie
• Bristol-Myers Squibb
• Johnson & Johnson
• Amgen
• Novo Nordisk

The organization's own words

PhRMA opposes the IRA's drug-price provisions as a threat to research incentives. In its late-2022 member survey, 63% of respondents expected to shift investment away from small molecules and 78% expected to cancel early-stage projects.

PhRMA · published 2023-01-17 · inspected 2026-09-13 · verified

Correction: 63% and 78% are respondents' stated expectations, not measured outcomes and not an independent causal finding. The survey drew responses from 25 of 33 member companies. The previous wording ('63% shifted', '78% planned to cancel') presented an advocacy survey's forecast as a result.

Center Forward

Pharma front group

Coalition / trade association · Pharma industry

Backers and affiliations (association only)

• PhRMA ($4.5M donated 2016–2019, >25% of revenue)
• undisclosed corporate donors

The organization's own words

Center Forward describes its purpose as giving voice to the political center and helping centrist allies develop bipartisan policy solutions.

Center Forward · undated source · inspected 2026-09-13 · verified

Correction: The previous field mixed the organization's self-description with conclusions about its board and its function. Those are separate claims needing separate evidence and are now stated separately below.

Our analysis, not theirs

Our reading, not Center Forward's: its board has included PhRMA representatives from Forbes Tate Partners, and it spent on ads backing incumbents who narrowed Medicare drug-price negotiation. Donor, board and influence claims each need their own evidence; the receipts for the ad spending are on the flows below.

Pfizer Inc. PAC

Pro-pharma

PAC · Pharma industry · FEC C00016683

Identity verified. Committee totals for C00016683 were retrieved from FEC on 2026-09-13.

Ten years of this committee's reported finances

Backers and affiliations (association only)

• Pfizer Inc.

Contributes to candidates based on their views on issues that impact Pfizer and the presence of Pfizer facilities or employees in their districts or states.

No source citation on file for this stated position.

Our analysis, not theirs

A corporate PAC funded by employee contributions. Its finances are the PAC's, not Pfizer Inc.'s; company revenue, lobbying spend and PAC receipts are three different numbers and only the last is shown in the committee finances view.

What the money is saying

Chains that connect a specific funder to a specific recipient to a specific message are in the relationship record above, where each link has its own receipt. The notes below do not make that connection and are not presented as though they do.

Funder-level strategy (3)

These describe how a funder talks overall. None is evidence that any individual politician authored, received, or was the subject of the message.

stated position / lobbying narrative· Pharmaceutical Research and Manufacturers of America (PhRMA)

PhRMA brands Medicare drug-price negotiation as 'government price setting' threatening innovation. Its late-2022 member survey is the usual citation: 63% of respondents said they expected to shift investment away from small molecules and 78% said they expected to cancel early-stage projects. Those are stated expectations from an advocacy survey of 25 of 33 member companies, not measured outcomes, and the framing casts the change as a threat to future cures rather than a transfer of savings to patients. [source]

501(c)(4) undisclosed ad spending· Center Forward

Center Forward brands itself centrist while its board is stocked with corporate lobbyists, including two PhRMA representatives. It funneled undisclosed pharma funds into ~$2.24M in outside ads backing Sinema (2021) and Schrader (2022), both of whom blocked or narrowed negotiation, with no donor disclosure required. [source]

PAC strategy / majority targeting· Pharmaceutical Research and Manufacturers of America (PhRMA)

In 2022, pharma and health-product PACs directed 60% of their $13.7M in candidate contributions to Democrats, the majority caucus with power over drug-pricing law; 14 of the top 20 congressional pharma recipients were Democrats and 39 of the top 40 sat on health committees. Despite a record $380M in industry lobbying, the IRA still passed, but with a scope the industry could live with. [source]

Context, not attributed to any funder (1)

revolving door / post-Congress career

Schrader's career arc is the receipt: pharma's largest House ally on Energy & Commerce voted down negotiation, lost his primary despite $1M+ in industry outside spending, then joined Williams & Jensen, whose pharma clients include every major company that funded his campaigns. He now lobbies the institution he spent years shielding from reform. [source]

Read the framing carefully

The core asymmetry isn't simply that these lawmakers took pharma money and narrowed reform: it's that they represented constituents who supported Medicare drug negotiation at ~90% while recasting industry-backed positions as principled concerns about innovation. The dollar amounts are modest by Washington standards; the strategic timing of contributions relative to key votes is the tell, and Schrader's revolving-door move is the clearest receipt. Note the scale: the industry spent a record $380M and still couldn't kill the IRA. The spending bought a narrower bill (250 drugs down to 20), not a dead one.